ESTROGEN COMPOUNDS, COGNITION & DEMENTIA IN OLDER WOMEN

雌激素化合物，认知

• 批准号: 6167950
• 负责人: Kristine Yaffe
• 金额: $ 12.18万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6167950
• 关键词: aging; behavioral /social science research tag; biomarker; bone density; chemoprevention; clinical research; cognition; dementia; estrogen receptors; estrogens; female; hormone regulation /control mechanism; hormone therapy; human old age (65+); human subject; human therapy evaluation; neuropharmacology; neuroprotectants; postmenopause; psychopharmacology; receptor expression

DESCRIPTION (Adapted from the application): This is the first application for a Mentored Clinical Scientist Development Award from the University of California at San Francisco on behalf of Kristine Yaffe, M.D. The applicant s goal is to develop the multidisciplinary skills necessary to become a leading independent investigator in dementia research. Developmental plans include a program of course work, research seminars, and structured mentoring, as well as a research project directed toward prevention and treatment of cognitive decline and dementia in the elderly. Specifically, the applicant will investigate the role of estrogen-like drugs for prevention of preclinical cognitive decline and dementia. She has chosen studies of different methodologies (randomized trial, cross-sectional, and prospective) in order to answer several complementary questions and to further her understanding of the strengths and limitations of various study designs. This proposal has three specific aims: (1) To determine whether elderly women using postmenopausal estrogen have better baseline cognitive function and less cognitive decline over a six year period than women not taking estrogen, (2) To determine whether elderly women treated for four years with a new selective estrogen receptor modulator, raloxifene, have better cognitive function and less incidence of dementia than women treated with placebo, (3) To determine if biologic markers of estrogen status, such as bone mineral density, serum estradiol levels, and different estrogen receptor genotypes, are associated with cognitive function in elderly women. The specific aims will be achieved by analyzing data from the ongoing Study of Osteoporotic Fractures (SOF), a prospective study of nearly 10,000 elderly community-dwelling women, and from the Multicenter Osteoporosis Raloxifene Evaluation (MORE) trial of over 7,000 women who were randomized to raloxifene or placebo. Both studies include large numbers of elderly women who were not demented at baseline and who receive periodic cognitive testing during the studies. If this promising preventive intervention proves effective, millions of women could preserve their cognitive capacity and maintain their independence and quality of life. This award will foster the applicant's development towards becoming an independent investigator in aging research.

描述（根据应用程序改编）：这是第一个应用程序 获得大学的指导临床科学家发展奖 加利福尼亚州在旧金山代表克里斯汀·亚菲（Kristine Yaffe），医学博士 S目标是发展成为一个必要的多学科技能 领先的独立研究者痴呆症研究。 发展计划 包括课程工作，研究研讨会和结构化的计划 指导以及针对预防和 老年人认知能力下降和痴呆症的治疗。 具体来说， 申请人将研究雌激素样药物的作用 预防临床前认知下降和痴呆症。 她选择了 不同方法的研究（随机试验，横截面和 预期）为了回答几个补充问题和 她进一步理解了各种研究的优势和局限性 设计。 该提议具有三个特定的目的：（1）确定老年人是否是否 使用绝经后雌激素的妇女具有更好的基线认知功能 在六年内的认知能力下降少于女性不服用 雌激素，（2）确定是否接受过四年的老年妇女 一种新的选择性雌激素受体调节剂Raloxifene具有更好的 与接受治疗的女性相比 安慰剂，（3）确定雌激素状态的生物标志物（例如 骨矿物质密度，血清雌二醇水平和不同的雌激素 受体基因型与老年妇女的认知功能有关。 通过分析正在进行的研究的数据来实现具体目标 骨质疏松性裂缝（SOF），一项近10,000个前瞻性研究 老年社区妇女，以及多中心骨质疏松症 拉昔芬评估（更多）试验，对7,000多名随机妇女 要进行雷洛昔芬或安慰剂。 两项研究都包括大量老年人 未在基线痴呆且获得定期认知的妇女 研究期间的测试。 如果这种有希望的预防性干预 事实证明有效，数百万妇女可以保留其认知能力 并保持其独立性和生活质量。 这个奖项将促进 申请人的发展成为成为独立调查员 老化研究。